Introduction
Until recently the mechanisms that allowed the chief cells of the parathyroid glands to secrete parathyroid hormone (PTH) at a rate that is responsive to the extracellular calcium ion concentration (Ca 2+ o ) remained obscure (Brown 1991) . The cloning of an extracellular calcium ion-sensing receptor (CaR) from bovine parathyroid tissue has defined an important step in the regulatory pathway of this Ca 2+ o -responsive PTH secretion (Brown et al. 1993) . Renal tubular calcium reabsorption, secretion of calcitonin by the thyroidal C-cells and probably many other Ca 2+ oresponsive cellular functions are also dependent upon the CaR to permit the regulation of extracellular calcium homeostasis. In addition, three disorders of extracellular calcium homeostasis: familial benign (hypocalciuric) hypercalcaemia, neonatal severe hyperparathyroidism and autosomal dominant hypocalcaemia with hypercalciuria, are caused by abnormalities of CaR function (Pearce & Brown 1996) . The biochemical and molecular characteristics of the CaR, and its role in the pathogenesis of these and other human disorders will be reviewed.
Identification and structure of the CaR
As Ca 2+ o increases in vivo, there is a steep and sigmoidal decrease in PTH release (Brown 1991) . This decrease can also be observed in preparations of dispersed parathyroid cells, indicating that the property of calcium sensing is intrinsic to the parathyroid cell (Brown et al. 1979) . Several in vitro studies of parathyroid cells had observed an accumulation of inositol-1,4,5-trisphosphate (IP 3 ), and a biphasic increase in the cytosolic calcium concentration in response to increasing the concentration of Ca 2+ o or a variety of other polyvalent cations such as magnesium, gadolinium and neomycin (Brown et al. 1987 , 1990 , 1991 , Nemeth & Scarpa 1987 . The patterns of these responses were typical of those mediated through a G protein-coupled receptor (GPCR) and could not be inhibited by pertussis toxin, suggesting that a G protein of the G q class was involved in the downstream signalling pathway (Chen et al. 1989) . The observation that injection of bovine parathyroid mRNA into Xenopus laevis oocytes rendered them sensitive to elevations in Ca 2+ o and that this response could be monitored by measuring the calciumactivated chloride fluxes across the oocyte cell membrane (Shoback & Chen 1991 , Racke et al. 1993 , enabled Brown et al. (1993) to identify a 5·3 kb cDNA by expression cloning in this system using the non-membrane permeable cation gadolinium as an agonist instead of calcium. This cDNA was designated bovine parathyroid calcium-sensing receptor (BoPCaR1) and encoded a protein of 1085 amino acids, which responded to cationic agonists with IP 3 accumulation and an increase in cytosolic calcium, as observed in dispersed parathyroid cells. BoPCaR1 has three structural domains: a large N-terminal domain of 613 amino acids that contains nine potential N-linked glycosylation sites consistent with an extracellular location; a central core of 250 amino acids, containing seven hydrophobic helices characteristic of the G protein-coupled receptor superfamily; and a predominantly hydrophilic 222 amino acid C-terminus predicted to be cytoplasmic (Brown et al. 1993) . CaR gene homologues were subsequently identified from human adenomatous parathyroid tissue, human kidney, and from rat kidney and brain, using BoPCaR1 as a probe (Aida et al. 1995a , Garrett et al. 1995a , Riccardi et al. 1995 , Ruat et al. 1995 . The human and rat CaRs, which consist of 1078 and 1079 amino acids respectively, both show a highly conserved structure, with 93% amino acid identity to BoPCaR1 (Brown et al. 1993 , Aida et al. 1995a , Garrett et al. 1995a , Riccardi et al. 1995 , Ruat et al. 1995 . These CaRs also have homology to the brain metabotropic glutamate receptors (mGluRs), having 29% amino acid identity to the rat mGluR1 protein (Houamed et al. 1991 , Brown et al. 1993 , but are structurally unrelated to other G protein-coupled receptors (i.e. those of the aspartatearginine-tyrosine (DRY) motif-containing rhodopsin-like subfamily, or the PTH receptor-like subfamilies). The bovine, human and rat CaRs and members of the mGluR subfamily all have 20 conserved cysteine residues spread throughout their extracellular and transmembrane domains which suggests that both subgroups may share a common framework of secondary structure (Brown et al. 1993) .
Genomic organisation and chromosomal localisation
The human CaR gene has a coding region of 3234 bp which is contained within 6 exons, and spans 45 kb of genomic DNA ( Fig. 1) (Garrett et al. 1995a) . There is at least one 5 untranslated exon and the initiator codon, ATG coding for methionine, is within exon 2 (Garrett et al. 1995a) . The amino terminus consists of a 21 amino acid signal peptide, and the large extracellular domain of the CaR, which is encoded by exons 2 to 6, and the 5 end of exon 7 (Fig. 1) . The seven transmembrane domains and the intracellular tail of the receptor are all encoded within exon 7 of the gene. In situ hybridisation studies have shown that the CaR gene is located on chromosome 3q13·3-21 in man, chromosome 11 in the rat and chromosome 16 in the mouse ( Janicic et al. 1995a) .
Expression pattern, splicing variants and regulation
Initial studies demonstrated that the 5·3 kb BoPCaR1 mRNA was not only expressed in bovine parathyroids but also the cerebral cortex, cerebellum, renal cortex and medulla, and thyroid (Brown et al. 1993) . Subsequent studies revealed the presence of CaR transcripts in rat renal cortex and outer medulla, and in situ hybridisation studies further localised this to the cortical medullary rays and outer medulla, suggesting that the major site of intrarenal CaR expression was in the thick ascending limb of the nephron (Riccardi et al. 1995) . CaR mRNA expression has also been observed in human, rat and sheep thyroid parafollicular C-cells, rat and bovine (Pollak et al. 1993 , Garrett et al. 1995a . The remainder of exon 7 encodes the transmembrane domain region and the intracellular tail (hatched). The first exon(s) is non-coding. (B) Four different CaR cDNA variants have been cloned from human parathyroid adenoma tissue (5·2 and 4·0 kb; Garrett et al. 1995a) , human kidney (3·0; Aida et al. 1995a) , and medullary carcinoma of the thyroid cells (1·0; Freichel et al. 1996) . The 5·2 and 4·0 kb variants have the same coding sequences except for a 30 bp insertion prior to exon 6 in the 5·2 kb cDNA. In contrast they have different 5 and 3 untranslated regions (UTR). The 3·0 kb cDNA lacks exons 4 and 5 (Aida et al. 1995a) , whilst the 1·0 kb cDNA fragment skips exon 3 and is predicted to translate exon 4 out of frame, thereby leading to a premature stop codon and a truncated protein (Freichel et al. 1996) .
testis, and in rat lung, ileum, large intestine, adrenal gland, and the central nervous system (Garrett et al. 1995b , Riccardi et al. 1995 , Ruat et al. 1995 , Freichel et al. 1996 . In the rat brain, CaR mRNA has been observed in the hypothalamus, corpus striatum, pituitary, cerebellum, cortex and hippocampus, and detailed immunohistochemical investigations have demonstrated CaR staining associated with nerve terminals and perivascular nerve plexi in these areas (Ruat et al. 1995) . Thus, CaR expression is surprisingly widespread and not simply confined to tissues with an obvious role in extracellular calcium homeostasis.
Several CaR mRNA transcripts have been identified in a variety of tissues from different species with the predominant transcript in bovine and human tissues being about 5·5 kb in size (Brown et al. 1993) . A 9·5-10 kb mRNA transcript has also been reported at a lower abundance in both human kidney and parathyroid adenoma tissue (Aida et al. 1995a , Garrett et al. 1995a ). In the rat, a major transcript of about 7·0-8·5 kb appears to predominate in kidney, thyroid, parathyroid and brain, with lower levels of a smaller 4·0 kb mRNA species also being present (Riccardi et al. 1995 , Ruat et al. 1995 . cDNA cloning from human tissues has demonstrated the presence of several different forms of CaR transcripts, with cDNAs of 5·2 and 4·0 kb, which have different 5 and 3 untranslated regions, in parathyroid adenoma tissue ( Fig. 1) (Garrett et al. 1995a ). In addition to the different untranslated sequences, the 5·2 kb form of the receptor cDNA appears to have a ten amino acid insertion prior to exon 6 ( Fig. 1) (Garrett et al. 1995a) . Two other splicing variants have also been identified, the first from human kidney, which lacks exons 5 and 6, and the second from a medullary thyroid carcinoma cell line, which lacks exon 3 and has a frameshift predicting a truncated protein ( Fig. 1 ) (Aida et al. 1995a , Freichel et al. 1996 . The functional significance of these alternate transcripts found in different tissues remains to be determined.
The regulation of CaR mRNA expression has been investigated by in vivo studies in the rat, and by in vitro studies using cultured bovine parathyroid cells, and the mouse pituitary cell line AtT-20. Studies of parathyroid and kidney tissue in vitamin D-deficient rats have shown that there is no variation in the expression of CaR mRNA over a range of plasma Ca 2+ o from 0·69 to 1·89 m, as assessed by a sensitive RNA solution hybridisation technique (Rogers et al. 1995) . Similarly, levels of CaR mRNA were constant in both parathyroid and kidney over a large range of different 1,25-dihydroxyvitamin D 3 infusion rates in rats (Rogers et al. 1995) . Thus, it seems that parathyroid and renal CaR expression is not influenced by the extracellular calcium or vitamin D concentrations. This is in contrast to the observations in the mouse pituitary AtT-20 cell line, in which CaR expression shows about a fourfold increase after incremental changes in Ca 2+ o from 0·3 to 2·0 m (Emanuel et al. 1996) . However, in dispersed fresh bovine parathyroid cells, the loss of the ability to suppress PTH release in response to increasing Ca 2+ o over the course of 3 to 6 days in culture is paralleled by rapid reductions in CaR expression as assessed by Northern, solution hybridisation and immunocytochemical analyses (Brown et al. 1995 , Mithal et al. 1995 . Thus, it seems that CaR expression is necessary for Ca 2+ o -responsive PTH secretion in vitro.
Disorders due to loss of CaR function
Two disorders, familial benign (hypocalciuric) hypercalcaemia (FBH) and neonatal severe hyperparathyroidism (NSHPT), have been associated with loss of CaR function. FBH is an autosomal dominant disorder characterised by lifelong and generally asymptomatic hypercalcaemia (Marx et al. 1981 , Law & Heath 1985 . Other biochemical features include mild hypermagnesaemia, normal or mildly elevated serum PTH levels and an inappropriately low urinary calcium excretion (calcium clearance to creatinine clearance ratio <0·01) (Marx et al. 1981 , Law & Heath 1985 . The disorder is considered to be benign as patients with FBH are usually asymptomatic. However, there is an increased prevalence of chondrocalcinosis with advancing age and occasional cases of acute pancreatitis have been reported (Davies et al. 1981 , Marx et al. 1981 ). An association of a progressive elevation in serum PTH concentration, hypophosphataemia and osteomalacia with FBH in a five-generation FBH kindred from Oklahoma has also been documented (McMurtry et al. 1992) . In contrast to the benign course of FBH, NSHPT is a life-threatening disorder characterised by severe neonatal hypercalcaemia, failure to thrive, bony undermineralisation, multiple fractures and rib cage deformity (Hillman et al. 1964 , Steinmann et al. 1984 , Heath 1994 . NSHPT was recognised amongst some children born to consanguineous FBH parents and was thus considered to be the homozygous phenotype of FBH (Marx et al. 1982) . Investigations of the primary defect causing FBH had previously revealed an altered 'set point' for the regulation of PTH by ionic calcium, which suggested that an abnormality in calcium sensing could be involved (Auwerx et al. 1984 , Khosla et al. 1993 . In addition, genetic linkage studies mapped FBH to the long arm of chromosome 3 (Chou et al. 1992 , Heath et al. 1993 , and to the same region that the human CaR gene was later localised.
Mutational analyses of the human CaR have revealed 22 different mutations in patients with FBH, and approximately two-thirds of the FBH kindreds investigated have been found to have unique heterozygous mutations of the CaR (Fig. 2) (Pollak et al. 1993 , Aida et al. 1995b , Chou et al. 1995 , Janicic et al. 1995b , Pearce et al. 1995 , Heath et al. 1996 . Many of these mutations cluster around the aspartate-and glutamate-rich regions (codons 39-300) within the extracellular domain of the receptor (Fig. 2) Calcium-sensing receptor: calcium homeostasis · S H S PEARCE and R V THAKKER 373 (Pollak et al. 1993 , Aida et al. 1995b , Chou et al. 1995 , Janicic et al. 1995b , Pearce et al. 1995 , Heath et al. 1996 , and this has been proposed to contain low affinity calciumbinding sites, based on similarities to those of calsequestrin, in which the ligand-binding pockets also contain negatively charged amino acid residues (Fliegel et al. 1987) . One FBH family with a nonsense mutation predicting a truncated CaR (Pearce et al. 1995) , and another with a large insertion have been found ( Janicic et al. 1995b) , and this suggested that CaR mutations associated with FBH were due to a loss of function. Expression studies of the missense CaR mutations associated with FBH, in both the Xenopus system and in human embryonic kidney cells , have demonstrated either a total loss of CaR function or a rightward shift in the 'set point' for Ca 2+ odependent IP 3 or intracellular calcium responses (Pollak et al. 1993 , Bai et al. 1996 , Heath et al. 1996 , Pearce et al. 1996a . Thus, loss of function CaR mutations cause an increase in the set point for Ca 2+ o -responsive PTH release and, presumably, elevate the renal calcium reabsorption at any given level of serum calcium, leading to the hypercalcaemia and hypocalciuria found in FBH. The remaining one-third of FBH families in whom a mutation within the coding region of the CaR has not been demonstrated may either have an abnormality in the promoter or other untranslated regions of the gene, or a mutation at one of the two other FBH loci that have been revealed by family linkage studies. One of these FBH loci is located on chromosome 19p and is referred to as FBH 19p (Heath et al. 1993 ). However, similar linkage studies of the FBH family from Oklahoma, which also suffered from progressive elevations in PTH, hypophosphataemia and osteomalacia, demonstrated that this variant, referred to as FBH Ok , was not linked to chromosomes 3q13-21 or 19p and there is therefore a third FBH locus that remains to be defined (Trump et al. 1995) .
NSHPT occurring in the offspring of a consanguineous FBH family has been shown to be due to homozygous CaR mutations (Pollak et al. 1993 , Janicic et al. 1995b , and a murine model with a targeted disruption of the CaR gene shows mild hypercalcaemia in heterozygotes and severe hyperparathyroidism with reduced viability in homozygotes, consistent with this finding (Ho et al. 1995) . However, three patients with sporadic neonatal hyperparathyroidism have been reported with de novo heterozygous CaR mutations (Fig. 2) (Pearce et al. 1995 , Bai et al. 1997 , suggesting that factors other than mutant gene dosage (Pollak et al. 1994a) , for example, the degree of set-point abnormality caused by the mutation or the maternal extracellular calcium concentration, may also play a role in the phenotypic expression of a CaR mutation in the neonate (Pearce et al. 1995 , Pearce & Brown 1996 , Bai et al. 1997 . In addition, these findings raise the possibility that a substantial number of cases of sporadic hypercalcaemia in infancy may be due to de novo CaR mutations.
Disorders due to gain of CaR function
As CaR mutations that result in a loss of function are associated with familial benign (hypocalciuric) hypercalcaemia (Pollak et al. 1993 , Aida et al. 1995b , Chou et al. 1995 , Janicic et al. 1995b , Pearce et al. 1995 , Heath et al. 1996 , it was speculated that CaR mutations that resulted in a gain of function may lead to hypocalcaemia with (Pollak et al. 1993 , Aida et al. 1995b , Chou et al. 1995 , Janicic et al. 1995b , Pearce et al. 1995 , Heath et al. 1996 , and ADHH mutations as open circles (Pollak et al. 1994b , Perry et al. 1994 , Baron et al. 1996 , Lovlie et al. 1996 , Pearce et al. 1996b . The open triangle represents the 1 bp deletion of the P747 frameshift mutation in NSHPT (Pearce et al. 1995) , and the solid triangle represents a 383 bp insertion found in an FBH/NSHPT kindred (Janicic et al. 1995b) . Amino acids are shown in the conventional one-letter code: i.e. A alanine, C cysteine, D aspartate, E glutamate, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine.
hypercalciuria. Investigations of 13 kindreds with autosomal dominant forms of hypocalcaemia have identified such CaR mutations (Fig. 2) (Pollak et al. 1994b , Perry et al. 1994 , Baron et al. 1996 , Lovlie et al. 1996 , Pearce et al. 1996b . Some affected individuals from these families were asymptomatic (Pollak et al. 1994 , Pearce et al. 1996b ), but some others had suffered from seizures, which generally occurred spontaneously in the neonatal period or before the age of 3 years and were associated with a febrile illness (Baron et al. 1996 , Lovlie et al. 1996 , Pearce et al. 1996b . Other symptoms such as tetany or muscle cramps have been reported in some members of these kindreds. Biochemical investigations revealed hypocalcaemia (total serum calcium=1·5 to 2·0 mmol/l), with associated hypomagnesaemia and serum PTH concentrations that were within the normal range (Baron et al. 1996 , Pearce et al. 1996b . Treatment with vitamin D or its active metabolites to correct the hypocalcaemia resulted in marked hypercalciuria, which led to nephrocalcinosis, nephrolithiasis and renal impairment in some patients (Baron et al. 1996 , Pearce et al. 1996b . After cessation of the vitamin D treatment, in most cases the renal impairment was reversible, although the nephrocalcinosis persisted (Pearce et al. 1996b) . Another notable feature in several affected individuals was the occurrence of thirst and polyuria when normocalcaemia was restored by vitamin D treatment (Pearce et al. 1996b ). In the 13 kindreds reported with this syndrome of autosomal dominant hypocalcaemia with hypercalciuria (ADHH), ten different mutations of the CaR have been found in 11 families (Fig. 2) (Pollak et al. 1994b , Perry et al. 1994 , Baron et al. 1996 , Lovlie et al. 1996 , Pearce et al. 1996b ). All of these ten mutations were missense, and eight of them were located within the extracellular domain of the receptor and only one was found in a transmembrane domain, with the remaining mutation being located in the first extracellular loop (Pollak et al. 1994b , Perry et al. 1994 , Baron et al. 1996 , Lovlie et al. 1996 , Pearce et al. 1996b . Functional studies in human embryonic kidney cells (HEK-293) have confirmed that these mutations produce a left-shift in the dose-response curve for Ca 2+ o -stimulated IP 3 and intracellular calcium responses, consistent with a gain of CaR function (Bai et al. 1996 , Pearce et al. 1996a . Thus, it is important to distinguish such patients from those with hypoparathyroidism, by a combination of clinical and molecular genetic studies, as vitamin D treatment to restore normocalcaemia in ADHH individuals leads to a high incidence of renal complications.
CaR abnormalities in other disorders

Acquired hyperparathyroidism
Because germline CaR mutations were associated with hypercalcaemia, and subjects with primary and uraemic tertiary hyperparathyroidism show an increase in the set-point for Ca 2+ o -responsive PTH suppression, it was suspected that the CaR may have a role in the pathogenesis of acquired hyperparathyroidism. Initial studies demonstrated that allelic deletions of the long arm of chromosome 3 occurred in about 10% of parathyroid adenomas and carcinomas (Thompson et al. 1995) , suggesting that somatic CaR gene deletions might be important. However, detailed CaR gene analysis of 44 parathyroid tumours, including both adenomas and carcinomas, has failed to reveal any CaR gene mutations (Hosokawa et al. 1995) . However, CaR immunostaining studies of parathyroid tumours and adjacent normal parathyroid tissue from patients with both primary and uraemic tertiary hyperparathyroidism have shown that there is between a 35 to 70% reduction in immunostainable CaR on the surface of the tumour cells, as compared with control tissue from the same patient (Kifor et al. 1996) . Thus, although the CaR gene is neither mutated nor deleted in acquired hyperparathyroidism, it appears that levels of CaR protein are reduced, suggesting that a reduction in CaR expression, caused by as yet undetermined factors, might be important in the reduced Ca 2+ o -responsive PTH suppression found in these disorders.
Autoimmune hypoparathyroidism
Autoimmune hypoparathyroidism is characterised by hypocalcaemia and hyperphosphataemia caused by a deficiency of PTH. It is most commonly encountered as a nearly invariant feature of the type 1 polyendocrinopathy syndrome (also referred to as the autoimmune polyendocrinopathy, candidiasis and ectodermal dysplasia (APECED) syndrome) in association with candidiasis, autoimmune adrenal failure, pernicious anaemia and autoimmune gonadal failure (Ahonen et al. 1990) . It may also occur sporadically, or in association with other autoimmune diseases such as Hashimoto's thyroiditis or type 1 diabetes. Although serum from some individuals with autoimmune hypoparathyroidism had been known to react against parathyroid tissue, the antigen that the serum antibodies were directed against has not been defined (Blizzard et al. 1966) . Recently, immunoblotting studies using native human parathyroid membranes, cell lines transfected with the CaR cDNA and in vitro translated CaR protein have demonstrated that sera from up to 14 of 25 individuals with autoimmune hypoparathyroidism specifically recognise an epitope within the extracellular domain of the CaR (Li et al. 1996) . These studies suggest that the CaR may be a key antigen in directing the immune response against parathyroid tissue in this condition.
Therapeutic manipulation of the CaR
Activation of the CaR, caused by small changes in the serum calcium concentration, appears to be the major Calcium-sensing receptor: calcium homeostasis · S H S PEARCE and R V THAKKER 375 regulator of the rate of PTH secretion from the parathyroid chief cells on a minute to minute basis, and probably over longer periods of time. The possibility of developing CaR agonist and antagonist compounds, which may allow PTH secretion to be regulated independently of the serum calcium, holds much promise for the medical treatment of several disorders. Initial studies have demonstrated that a CaR agonist (NPS R-568), also referred to as a calciumimetic, causes hypocalcaemia when administered to rats, and that it inhibits both PTH secretion and reduces PTH mRNA levels in bovine parathyroid cells in vitro (Fox et al. 1994 , Garrett et al. 1995c . Furthermore, this compound has been demonstrated to prevent the development of secondary hyperparathyroidism in 5/6th-nephrectomised rats (Fox et al. 1995) , suggesting that it may be of use in the prevention of renal osteodystrophy as well as in the treatment of primary hyperparathyroidism. Clinical trials to establish the therapeutic potential of this CaR agonist are in progress. In addition, the future development of CaR antagonists may also hold promise for the treatment of other common disorders such as osteoporosis.
Summary
The cloning of the BoPCaR1 gene has helped to elucidate many aspects of normal extracellular calcium homeostasis, particularly as applied to the regulation of PTH secretion, calcitonin secretion and renal calcium reabsorption. In addition, loss and gain of function mutations have been found to cause the clinical syndromes of FBH, NSHPT and ADHH respectively. The CaR has also been implicated in the mechanisms leading to primary and uraemic hyperparathyroidism, and autoimmune parathyroid destruction. The recent demonstration that the CaR regulates non-selective cation channel function in rat hippocampal neurones suggests that it may also have a role within the central nervous system that is entirely unrelated to calcium homeostasis (Ye et al. 1996) . Finally, the prospect of CaR agonists and antagonists, which may allow PTH secretion to be regulated independently of the serum calcium concentration, also holds much promise for the medical treatment of hyperparathyroidism, renal osteodystrophy and osteoporosis. 
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